The Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors
NCT ID: NCT05219851
Last Updated: 2024-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
250 participants
OBSERVATIONAL
2022-06-01
2025-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer
NCT03035890
Study on the Biological Prediction Models of Radiation Pneumonitis
NCT02490319
Risk Factors of Radiation Pneumonitis
NCT00155909
Biomarkers for Prediction of Tumor Response to Radiotherapy
NCT03744819
Investigating the Tumour Immune Response of Radiotherapy
NCT05076500
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Risk factors (especially analysis of the dosimetric risk factor) which may affect the product of aRPs events.
3. Establish a model to predict aRPs and guide clinical treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cancer patients underwent thoracic intensity-modulated radiotherapy
Cancer patients underwent thoracic intensity-modulated radiotherapy, previously received ICIs
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Cancer patients with previously received ICIs underwent thoracic intensity-modulated radiotherapy
Exclusion Criteria
2. Non-thoracic radiotherapy patients
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hubei Cancer Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
HAN GUANG
Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hubei Cancer Hospital
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Guang Han, MD.Phd
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HBCH-RT-2022-RP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.